Next-Gen Biomarker Discovery

About Aspira Women's Health

Aspira Women's Health is a public company focused on transforming the clinical management of ovarian adnexal masses through its AI-driven multivariate index assays (MIAs). Its core achievement is the commercial OvaSuite portfolio, including Ova1, Overa, and OvaWatch, which have demonstrated superior sensitivity over CA-125 alone and are supported by over 200,000 tests performed. The company's strategy centers on expanding adoption of its tests within established clinical guidelines, leveraging its growing dataset to refine its algorithms, and pursuing new biomarker discoveries to solidify its leadership in gynecologic diagnostics.

Therapeutic Areas